Referencias bibliográficas
- Benoit R., et al. (2022). Compendio de monografías 2022 fórmulas para estrategias basadas en la medicina funcional. Ediciones de Medicina Funcional. Pag 53-73. ISBN: 978-958-52245-1-3
- Medina D.X., et al. (2010). Methylene Blue Reduces Ab Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity. Brain Pathology. doi:10.1111/j.1750-3639.2010.00430.x
- Rodriguez, P., et al. (2017). Methylene blue modulates functional connectivity in the human brain. Brain Imaging and Behavior. 11(3): 640–648. doi:10.1007/s11682-016-9541-6.
- Tucker, D., et al. (2018). From Mitochondrial Function to Neuroprotection – An Emerging Role for Methylene Blue. Molecular Neurobiology. 55(6): 5137–5153. doi:10.1007/s12035-017-0712-2
- VandeVedrea, L., et al. (2020). Targeting tau: ensayos clínicos y nuevos enfoques terapéuticos. Neurocienses Letter. 731: 134919. doi:10.1016/j.neulet.2020.134919
- Wischik, C.M., et al. (2015). Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer’s Disease. Journal of Alzheimer’s Disease 44 (2015) 705–720 DOI 10.3233/JAD-142874
- World Health Organization. (2020). Dementia. Retrieved from [https://www.who.int/news-room/fact-sheets/detail/dementia](https://www.who.int/news-room/fact-sheets/detail/dementia)
